INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $614,394 | +45.2% | 9,703 | +6.7% | 0.08% | +21.9% |
| Q3 2022 | $423,000 | -28.3% | 9,090 | -12.1% | 0.06% | -13.5% |
| Q2 2022 | $590,000 | -7.4% | 10,339 | -0.7% | 0.07% | +1.4% |
| Q1 2022 | $637,000 | +14.0% | 10,416 | -2.4% | 0.07% | +19.7% |
| Q4 2021 | $559,000 | +179.5% | 10,674 | +36.9% | 0.06% | +90.6% |
| Q3 2020 | $200,000 | +344.4% | 7,795 | +112.2% | 0.03% | +300.0% |
| Q1 2019 | $45,000 | -61.9% | 3,673 | -64.6% | 0.01% | -66.7% |
| Q4 2018 | $118,000 | -79.5% | 10,386 | -60.8% | 0.02% | -75.3% |
| Q3 2018 | $575,000 | +12.7% | 26,486 | -8.2% | 0.10% | +5.4% |
| Q2 2018 | $510,000 | -17.1% | 28,850 | -1.3% | 0.09% | -18.6% |
| Q1 2018 | $615,000 | +46.4% | 29,238 | +0.8% | 0.11% | +46.8% |
| Q4 2017 | $420,000 | – | 29,016 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |